Trials / Unknown
UnknownNCT03322735
Study of BCMA CAR-T in Multiple Myeloma
A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fludarabine | 25-30mg/m2/day IV for 3 days |
| DRUG | Cyclophosphamide | cyclophosphamide 0.6-0.8g/m2/day IV for 2 days |
| BIOLOGICAL | BCMA CAR-T | BCMA CAR-T cells will be administered after completion of the chemotherapy. |
Timeline
- Start date
- 2017-12-08
- Primary completion
- 2018-10-01
- Completion
- 2019-12-01
- First posted
- 2017-10-26
- Last updated
- 2017-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03322735. Inclusion in this directory is not an endorsement.